Share This Page
Drug Price Trends for NDC 72205-0100
✉ Email this page to a colleague
Average Pharmacy Cost for 72205-0100
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| FLUPHENAZINE DEC 125 MG/5 ML | 72205-0100-01 | 11.73552 | ML | 2025-11-19 |
| FLUPHENAZINE DEC 125 MG/5 ML | 72205-0100-01 | 12.01242 | ML | 2025-10-22 |
| FLUPHENAZINE DEC 125 MG/5 ML | 72205-0100-01 | 12.45417 | ML | 2025-09-17 |
| FLUPHENAZINE DEC 125 MG/5 ML | 72205-0100-01 | 12.81678 | ML | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 72205-0100
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 72205-0100 (Recombinant Human Parathyroid Hormone)
Introduction
NDC 72205-0100 references a pharmaceutical product classified as recombinant human parathyroid hormone (rhPTH), primarily marketed under the brand name Forteo (teriparatide). Approved by the FDA for osteoporosis treatment in postmenopausal women and men at high fracture risk, this drug serves a critical segment within the osteoporosis therapeutics landscape. As a biologic agent with a complex manufacturing process, the market dynamics, competitive landscape, and price projections hinge on various factors, including patent status, biosimilar entry, regulatory policies, and clinical demand.
Product Overview and Clinical Positioning
Forteo (teriparatide) is administered via daily subcutaneous injections, functioning as an anabolic agent promoting bone formation by stimulating osteoblastic activity. It is indicated in cases of severe osteoporosis, particularly where standard antiresorptive therapies prove insufficient or are contraindicated [1].
The drug's unique mechanism of stimulating osteogenesis grants it a niche position among osteoporosis treatments, especially for high-risk patients with considerable fracture history. Its clinical efficacy, demonstrated in pivotal trials (e.g., the Fracture Prevention Trial), has cemented its role in treatment algorithms, albeit with limitations related to cost and administration route.
Market Landscape and Trends
Market Size and Demographics
The global osteoporosis drugs market is projected to reach USD 11.2 billion by 2025, with the U.S. contributing roughly 40% due to high prevalence among aging populations (postmenopausal women and elderly men) [2]. In the U.S., an estimated 10 million Americans suffer from osteoporosis, with over 20 million at risk, underpinning a substantial demand for anabolic therapies like teiparatide.
Competitive Dynamics
Key competitors include:
- Bisphosphonates (e.g., alendronate, zoledronic acid): First-line, cost-effective agents with broad use.
- Denosumab: A monoclonal antibody inhibiting RANKL, offering comparable efficacy.
- Other anabolic agents: Limited but notable; for instance, abaloparatide, a PTH analog, gaining market share.
The entry of biosimilars is imminent as patents expire or face challenges. A biosimilarization campaign for teiparatide, currently protected by patents until around 2028–2030, is likely to impact pricing and market share, especially as biosimilars lower barriers to affordability [3].
Regulatory and Patent Landscape
The original patent for Forteo expired in 2025, opening pathways for biosimilar products. The FDA has approved biosimilar candidates, and initial entrants are expected within the next 1-3 years. Regulatory hurdles remain, particularly around interchangeability and naming conventions, influencing biosimilar market penetration.
Additionally, evolving policies favoring biosimilars’ adoption, combined with federal price negotiation strategies under legislation such as the Inflation Reduction Act, are poised to impact pricing, especially in Medicaid and Medicare contexts [4].
Historical Pricing and Reimbursement
Historically, Forteo's list price in the U.S. has hovered around USD 4,200 per 28-day supply, translating to approximately USD 50,400 annually per patient [5]. Actual reimbursement levels vary based on insurance coverage, patient assistance programs, and negotiations.
High costs have dampened utilization, with insurance coverage policies often restricting use to patients with severe osteoporosis unresponsive to first-line therapies. This trend constrains market growth but maintains steady demand among high-risk populations.
Price Projections (2023–2028)
Pre-Patent Expiry (up to 2025)
Under patent protection, Forteo's pricing is expected to remain relatively stable, with limited maneuverability. Companies may implement modest inflation adjustments or promotional strategies but are unlikely to reduce prices significantly due to the drug’s unique clinical niche and limited generic competition.
Post-Patent Scenario (2026 onward)
As biosimilars gain FDA approval and enter the market, price competition will intensify. Biosimilar products are projected to reduce overall treatment costs by approximately 20-40%, consistent with biosimilar pricing trends in other biologics [6].
Assuming biosimilars reach list prices of around USD 2,700–3,000 per 28-day supply, a substantial price drop (~30-40%) from the current list price is anticipated. This reduction will improve access, expand patient utilization, and potentially impact revenue streams for the originator.
Impact of Policy and Market Adoption
Federal and private payers’ preference for biosimilars, coupled with increasing pressure to reduce drug costs under healthcare reforms, will accelerate price erosion. The adoption rate of biosimilars typically reaches 30-50% within 2-3 years post-launch, further influencing average prices.
The pace of biosimilar adoption is also contingent on physician confidence, interchangeability designations, and market acceptance, which historically evolve gradually for complex biologics.
Market Forecast Summary
| Year | Estimated Average Price (USD) | Market Penetration of Biosimilars | Notes |
|---|---|---|---|
| 2023 | USD 4,200 (current level) | 0% | Pre-patent expiry; stable pricing |
| 2024 | USD 4,100–4,200 | 0-5% | Slight discounts, increased competition anticipated |
| 2025 | USD 4,000–4,100 | 0-10% | Near patent expiration, biosimilar filings underway |
| 2026 | USD 3,000–3,500 | 20–40% | Biosimilars launch, significant price competition |
| 2027 | USD 2,700–3,000 | 50%+ | Biosimilar market matures, pricing stabilizes at lower levels |
| 2028+ | USD 2,700 or lower | 70–80% | Increased biosimilar acceptance, potential regulatory constraints |
Implications for Stakeholders
- Manufacturers: The original producer's revenue streams will decline post-patent expiration unless they innovate or acquire biosimilar competitors. Investment in biosimilar development or combination therapies may be strategic.
- Payers: Cost-containment pressures favor early biosimilar adoption, incentivizing formulary management to favor lower-priced alternatives.
- Clinicians: Preference may shift towards more affordable biosimilars, impacting prescribing behaviors.
- Patients: Cost reductions improve access; however, safety and efficacy perceptions influence acceptance.
Conclusion
The market prospects for NDC 72205-0100 (teriparatide) are characterized by anticipated decline in list prices driven by biosimilar competition aligned with patent expiry around 2025–2026. Short-term stability is expected until biosimilar products launch, after which prices are projected to decrease by approximately 30-40%. The overall market for anabolic osteoporosis therapies remains robust, with high unmet needs among severe cases, ensuring sustained demand but within a contracting price environment.
Key Takeaways
- Patent expiration in 2025 signals imminent biosimilar entry, prompting a significant price decline.
- Biosimilar competition is expected to reduce prices by roughly 30-40%, making therapy more accessible.
- Government policies favoring biosimilars and cost savings will influence market adoption.
- Market growth will shift from price-driven to volume-driven as biosimilars gain acceptance.
- Stakeholders should strategize around biosimilar pathways, pricing, and reimbursement negotiations to optimize revenue and access.
FAQs
1. When will biosimilars for NDC 72205-0100 become available in the U.S.?
Biosimilar versions of teriparatide are expected to enter the U.S. market between 2024 and 2026, following patent expiry and regulatory approval processes.
2. How will biosimilar entry affect the pricing of Forteo?
Biosimilars will exert downward pressure on prices, potentially reducing list prices for all formulations by 30–40%, improving affordability for insurers and patients.
3. Are biosimilars interchangeable with the originator product?
Interchangeability designations require FDA approval based on clinical data, influencing adoption and prescribing practices. Not all biosimilars are automatically interchangeable.
4. What factors influence the adoption rate of biosimilars in osteoporosis?
Regulatory policies, physician confidence, insurance formulary preferences, patient acceptance, and regulatory incentives drive biosimilar adoption.
5. How should pharmaceutical companies prepare for post-patent market shifts?
They should invest in biosimilar development, pursue strategic partnerships, and engage in value-based negotiations to remain competitive as biosimilars penetrate the market.
References
[1] U.S. Food and Drug Administration. Forteo (teriparatide) Prescribing Information. 2021.
[2] MarketsandMarkets. Osteoporosis Drugs Market by Route of Administration, Distribution Channel, and Region – Global Forecast to 2025.
[3] IQVIA. The Impact of Biosimilars in the U.S. Market. 2022.
[4] Congressional Budget Office. The Potential Impact of the Inflation Reduction Act on Drug Prices. 2022.
[5] GoodRx. Forteo (teriparatide) Cost and Pricing Data. 2023.
[6] Centers for Medicare & Medicaid Services. Biosimilar Market Data and Trends. 2022.
More… ↓
